Azenta, Inc.
Rank #415StartupAZTA · Nasdaq · Healthcare
Azenta, Inc. (AZTA) — Rank #415 by gross profitability (GP/assets 0.14) · ROE -3.7% · Piotroski F-Score N/A.
As-of 2026-09-15 · CIK 0000933974 · all metrics point-in-time as of the filing date.
About
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences industry in the United States, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally.
Show moreShow less
It operates through Sample Management Solutions and Multiomics segments. The Sample Management Solutions segment provides sample management products and services, including automated stores, cryogenic systems, automated sample tubes, consumables and instruments, and controlled rate thawing devices, as well as sample repository services. This segment also offers consultation services to clients throughout their experimental design and implementation processes. The Multiomics segment provides genomic and other sample analysis services comprising gene sequencing, gene synthesis, and related services. The company has a strategic partnership with Frontier Space Ltd to conduct scientific experiments in space. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc.
was founded in 1978 and is headquartered in Burlington, Massachusetts.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- State
- DE
- Filer Category
- Large accelerated filer
- Fiscal Year End
- September 30
- Website
- azenta.com
Price History
Company Snapshot
P/S is the primary valuation lens for pre-profit companies.
Market Cap
$1.45B
P/E (annual)
—
P/S (annual)
2.4
P/B
1.0
P/OCF (annual)
20.1
Shareholder Yield
13.7%
Employees
2,900
Industry
Medical Instruments & Supplies
Exchange
Nasdaq
Signal Flags
Quality Profile
Profitability
1/1 passSafety
1/1 passCash Flow
3/3 passGrowth
2/2 passTerry Smith quality gate
Passes 0/5 Terry Smith thresholds2 of 5 thresholds not computable from filed data.
What Growth Is Priced In
Implied revenue growth (10Y)
17.1%
The annual FCF growth rate today's price requires over a 10-year horizon (discount rate 10%, terminal growth 2.5%).
Buyback tailwind: -13.7% — per-share value needs a total required return of 3.4% once share-count change is priced in.
vs. own 6-year median revenue growth: 11.5%
within its own historyCost-of-equity sensitivity (implied growth at different discount rates)
r = 8%
12.2%
r = 10% (base)
17.1%
r = 12%
21.3%
Net debt / market cap: -21.4%
Valuation History
Current multiple vs historical range at each filing date. Band spans 25th-75th percentile.
P / E
Price / diluted EPS
P / S
Price / revenue per share
P / B
Price / book value per share
P / GP
Price / gross profit per share
P / FCF
Price / free cash flow per share
Burn rate (cash flow) is the primary read at this stage — TAM and product-market fit aren't metrics this dashboard tracks.
Profitability
Gross profitability (GP / assets)
0.14
Primary signal (Novy-Marx).
6th pctl of 36 SIC 35 peers
Return on equity
-3.7%
Gross margin
45.5%
71st pctl of 36 SIC 35 peers
Revenue growth (YoY)
3.6%
RPO growth (YoY)
-45.0%
Remaining performance obligations growth — RPO > revenue = forward demand building.
Gross margin improving
Margin trend vs prior year.
Operating Leverage
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Revenue vs COGS | ||||
| Revenue vs OpEx | ||||
| Op. Income vs Revenue |
Growth
Revenue CAGR (3Y)
2.2%
Revenue CAGR (5Y)
8.9%
Earnings CAGR (3Y)
—
FCF CAGR (3Y)
—
Anti-fragile safety
Balance-sheet safety
Composite anti-fragile check.
Debt / equity
0.24
100th pctl of 36 SIC 35 peers (best = lowest)
Current ratio
2.50×
71st pctl of 36 SIC 35 peers
Quick ratio
1.72×
Net cash
$325.80M
Cash & equivalents minus total debt.
Cash-flow health
Free cash flow
$38.32M
Operating cash flow minus capex.
Positive free cash flow
FCF / net income
1.69
Cash-backing of earnings.
FCF/NI divergence
Unfavorable divergence (yellow flag).
Accruals healthy
Cash-backed earnings.
SBC / revenue
3.5%
Stock-based comp intensity.
Piotroski F-Score
F-Score
N/A
Only 8/9 components determinable.
Lifecycle Phase History
Lynch sell alert: Turnaround stalled
Classified startup for 2 consecutive fiscal years (2024-09-30, 2025-09-30) with no recovery to a healthier phase -- Lynch's turnaround rule: if it hasn't turned around by now, assume it isn't going to.